

## Special Issue

# Pharmacotherapy for Retinopathy

### Message from the Guest Editor

The mechanisms underlying retinopathy of prematurity (ROP) development, progression and recurrence have not been fully elucidated. As with most pathologic proliferative retinal vascular diseases, the blockage of vascular endothelial growth factor (VEGF) by an intravitreal injection has become the mainstay of treatment. Several anti-VEGF agents are in use for aggressive posterior ROP, and trials have indicated non-inferiority to laser photocoagulation. Although anatomic and functional outcomes may be improved with pharmacotherapy, recurrences are common, unpredictable and may lead to blindness. Furthermore, the disease presents lifelong risks of visual loss. In furtherance of advancing ROP treatment, we wish to better understand the role of VEGF blockade, the precise molecular switching mechanisms at play, inducible-factor interactions, nutrition and tissue-constitutive factors that play a role in the complex formation of pathologic neovascularization in ROP.

---

### Guest Editor

Dr. Eric Shrier

Department of Ophthalmology, State University of New York, Downstate Health Sciences University, Brooklyn, NY 11203, USA

---

### Deadline for manuscript submissions

closed (25 February 2025)



## Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/190551](https://mdpi.com/si/190551)

*Pharmaceuticals*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)

[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





## Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



## About the Journal

### Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

---

### Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)